Commerce Bank Sells 1,309 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Commerce Bank lowered its position in IQVIA Holdings Inc. (NYSE:IQV) by 1.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 70,731 shares of the medical research company’s stock after selling 1,309 shares during the period. Commerce Bank’s holdings in IQVIA were worth $16,761,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Versant Capital Management Inc increased its position in shares of IQVIA by 733.3% during the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 110 shares during the last quarter. Opal Wealth Advisors LLC bought a new stake in IQVIA during the second quarter valued at $27,000. Capital Performance Advisors LLP bought a new stake in IQVIA during the third quarter valued at $27,000. Park Place Capital Corp bought a new stake in IQVIA during the third quarter valued at $28,000. Finally, Itau Unibanco Holding S.A. purchased a new stake in IQVIA during the second quarter valued at about $29,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Stock Up 1.6 %

IQV stock opened at $194.38 on Thursday. The firm has a 50-day moving average of $224.22 and a two-hundred day moving average of $227.56. IQVIA Holdings Inc. has a 12 month low of $187.62 and a 12 month high of $261.73. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. The company has a market cap of $35.28 billion, a price-to-earnings ratio of 25.51, a PEG ratio of 1.97 and a beta of 1.51.

Wall Street Analysts Forecast Growth

IQV has been the topic of several analyst reports. TD Cowen decreased their price objective on IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Argus raised IQVIA to a “strong-buy” rating in a research report on Wednesday, July 31st. JPMorgan Chase & Co. cut their price objective on IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 5th. StockNews.com raised IQVIA from a “hold” rating to a “buy” rating in a research report on Wednesday. Finally, Barclays lowered their price objective on IQVIA from $260.00 to $255.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Four research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and a consensus target price of $256.50.

Insider Activity

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the sale, the insider now directly owns 19,536 shares in the company, valued at $4,812,302.88. This represents a 6.24 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.60% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.